Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571797 | 1.00 | OPRM1 (0.74) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29576785 | 0.96 | SLC6A2 (0.74) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29702054 | 0.95 | OPRM1 (0.66) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL31412199 | 0.95 | OPRM1 (0.66) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30833622 | 0.95 | OPRM1 (0.66) | OPRM1OPRD1SLC6A2 | |
| Morphiceptin SCHEMBL30128493 | 0.93 | OPRM1 (0.81) | OPRM1OPRD1 | |
| Morphiceptin SCHEMBL30523887 | 0.93 | OPRM1 (0.81) | OPRM1OPRD1 | |
| SCHEMBL38658663 | 0.93 | OPRM1 (0.78) | OPRM1OPRD1 | |
| SCHEMBL29368129 | 0.92 | OPRM1 (0.74) | OPRM1OPRD1 | |
| SCHEMBL29780362 | 0.92 | OPRM1 (0.69) | OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | claimed |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | disclosed |
| CN-118894918-B | Functional peptide with blood pressure reducing effect, and preparation method and application thereof | 澳优乳业（中国）有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | disclosed |
| CN-118894918-A | Functional peptide with blood pressure reducing effect, and preparation method and application thereof | 澳优乳业（中国）有限公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2024031163-A1 | USE OF PEPTIDES AND FORMULATION | UNIÃO BRASILEIRA DE EDUCAÇÃO CATÓLICA - UBEC (BR) | 2024-02-15 | — | — | WO | disclosed |
| EP-3716948-B1 | NOVEL ANALGESIC PHARMACEUTICAL FORMULATIONS AND USES THEREOF | CYTOGEL PHARMA LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-111647041-B | Endomorphin analogues and uses thereof | 南京医科大学 | 2023-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | VIP, SI, ALPI | OPRM1 4565/4885OPRD1 4793/4885SLC6A2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.